Lonza adds on small molecule facility at Visp site, adding new weight to its expansion plans on the back of a big year
In December, Swiss CDMO Lonza promised to increase its overall production capacity by 30% by the first half of 2022, and it planned to do so by expanding bioconjugation capabilities at its Visp, Switzerland facility. Now, it’s taking that expansion one step further and adding a 2,1528-square-foot small molecule complex at the same site.
The complex will include a customer-dedicated manufacturing line for antibody-drug conjugate (ADC) payload molecules, the first of its kind, according to the company. Operations will begin in 2023, Lonza said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.